+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Atrial Fibrillation R&D Pipeline Drugs and Companies- Analysis of Global Atrial Fibrillation Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4745225
  • Report
  • Region: Global
  • 85 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Acesion Pharma
  • AnaBios Corporation
  • Correvio Pharma Corp.
  • Edge Therapeutics Inc
  • G3 Pharmaceuticals Inc
  • InCarda Therapeutics Inc
  • MORE
The global demand for Atrial Fibrillation treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Atrial Fibrillation pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Atrial Fibrillation pipeline companies from advancing their products into Phase 3 or Phase 4.

Atrial Fibrillation Report Description

The H1- 2019 pipeline review report on Atrial Fibrillation pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Atrial Fibrillation pipeline compounds.

The Atrial Fibrillation pipeline guide presents information on all active drugs currently being developed for Atrial Fibrillation. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Atrial Fibrillation pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Atrial Fibrillation drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Atrial Fibrillation product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Atrial Fibrillation pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Atrial Fibrillation pipeline report includes
  • An overview of Atrial Fibrillation disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
For each pipeline product, the following details are provided
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Atrial Fibrillation pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Atrial Fibrillation pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Atrial Fibrillation pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acesion Pharma
  • AnaBios Corporation
  • Correvio Pharma Corp.
  • Edge Therapeutics Inc
  • G3 Pharmaceuticals Inc
  • InCarda Therapeutics Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Atrial Fibrillation Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Atrial Fibrillation Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Atrial Fibrillation pipeline, H1- 2019
3.5 Mechanism of Action wise Atrial Fibrillation Pipeline Candidates

4. Acesion Pharma Atrial Fibrillation Pipeline Details
4.1 Acesion Pharma Business Profile
4.2 Acesion Pharma Atrial Fibrillation Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. Aetas Pharma Atrial Fibrillation Pipeline Details
5.1 Aetas Pharma Business Profile
5.2 Aetas Pharma Atrial Fibrillation Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. Allosteros Therapeutics Inc Atrial Fibrillation Pipeline Details
6.1 Allosteros Therapeutics Inc Business Profile
6.2 Allosteros Therapeutics Inc Atrial Fibrillation Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. AnaBios Corporation Atrial Fibrillation Pipeline Details
7.1 AnaBios Corporation Business Profile
7.2 AnaBios Corporation Atrial Fibrillation Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. ARCA biopharma Inc Atrial Fibrillation Pipeline Details
8.1 ARCA biopharma Inc Business Profile
8.2 ARCA biopharma Inc Atrial Fibrillation Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. Boston Pharmaceuticals Inc Atrial Fibrillation Pipeline Details
9.1 Boston Pharmaceuticals Inc Business Profile
9.2 Boston Pharmaceuticals Inc Atrial Fibrillation Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. Correvio Pharma Corp. Atrial Fibrillation Pipeline Details
10.1 Correvio Pharma Corp. Business Profile
10.2 Correvio Pharma Corp. Atrial Fibrillation Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. Daiichi Sankyo Co Ltd Atrial Fibrillation Pipeline Details
11.1 Daiichi Sankyo Co Ltd Business Profile
11.2 Daiichi Sankyo Co Ltd Atrial Fibrillation Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. Dong-A Socio Holdings Co Ltd Atrial Fibrillation Pipeline Details
12.1 Dong-A Socio Holdings Co Ltd Business Profile
12.2 Dong-A Socio Holdings Co Ltd Atrial Fibrillation Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. Edge Therapeutics Inc Atrial Fibrillation Pipeline Details
13.1 Edge Therapeutics Inc Business Profile
13.2 Edge Therapeutics Inc Atrial Fibrillation Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14. Espero BioPharma Inc Atrial Fibrillation Pipeline Details
14.1 Espero BioPharma Inc Business Profile
14.2 Espero BioPharma Inc Atrial Fibrillation Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. G3 Pharmaceuticals Inc Atrial Fibrillation Pipeline Details
15.1 G3 Pharmaceuticals Inc Business Profile
15.2 G3 Pharmaceuticals Inc Atrial Fibrillation Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16. Gilead Sciences Inc Atrial Fibrillation Pipeline Details
16.1 Gilead Sciences Inc Business Profile
16.2 Gilead Sciences Inc Atrial Fibrillation Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17. HUYA Bioscience International Atrial Fibrillation Pipeline Details
17.1 HUYA Bioscience International Business Profile
17.2 HUYA Bioscience International Atrial Fibrillation Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18. InCarda Therapeutics Inc Atrial Fibrillation Pipeline Details
18.1 InCarda Therapeutics Inc Business Profile
18.2 InCarda Therapeutics Inc Atrial Fibrillation Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19. Merck & Co Inc Atrial Fibrillation Pipeline Details
19.1 Merck & Co Inc Business Profile
19.2 Merck & Co Inc Atrial Fibrillation Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20. N-Gene Research Laboratories Inc Atrial Fibrillation Pipeline Details
20.1 N-Gene Research Laboratories Inc Business Profile
20.2 N-Gene Research Laboratories Inc Atrial Fibrillation Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21. Nissan Chemical Industries Ltd Atrial Fibrillation Pipeline Details
21.1 Nissan Chemical Industries Ltd Business Profile
21.2 Nissan Chemical Industries Ltd Atrial Fibrillation Drug Details
21.2.1 Drug Snapshot
21.2.1.1 Originator
21.2.1.2 Collaborator/Co-Developer
21.2.1.3 Route of Administration
21.2.1.4 Orphan Drug/Fast Track/Special Designation
21.2.1.5 Area
21.2.1.6 Type of Molecular Entity
21.3 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22. OMEICOS Therapeutics GmbH Atrial Fibrillation Pipeline Details
22.1 OMEICOS Therapeutics GmbH Business Profile
22.2 OMEICOS Therapeutics GmbH Atrial Fibrillation Drug Details
22.2.1 Drug Snapshot
22.2.1.1 Originator
22.2.1.2 Collaborator/Co-Developer
22.2.1.3 Route of Administration
22.2.1.4 Orphan Drug/Fast Track/Special Designation
22.2.1.5 Area
22.2.1.6 Type of Molecular Entity
22.3 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23. The Geneva Biotech Center SA Atrial Fibrillation Pipeline Details
23.1 The Geneva Biotech Center SA Business Profile
23.2 The Geneva Biotech Center SA Atrial Fibrillation Drug Details
23.2.1 Drug Snapshot
23.2.1.1 Originator
23.2.1.2 Collaborator/Co-Developer
23.2.1.3 Route of Administration
23.2.1.4 Orphan Drug/Fast Track/Special Designation
23.2.1.5 Area
23.2.1.6 Type of Molecular Entity
23.3 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24. Verseon Corp Atrial Fibrillation Pipeline Details
24.1 Verseon Corp Business Profile
24.2 Verseon Corp Atrial Fibrillation Drug Details
24.2.1 Drug Snapshot
24.2.1.1 Originator
24.2.1.2 Collaborator/Co-Developer
24.2.1.3 Route of Administration
24.2.1.4 Orphan Drug/Fast Track/Special Designation
24.2.1.5 Area
24.2.1.6 Type of Molecular Entity
24.3 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

20. Latest Atrial Fibrillation Drug Pipeline Developments, 2019

21. Appendix
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acesion Pharma
  • Aetas Pharma
  • Allosteros Therapeutics Inc
  • AnaBios Corporation
  • ARCA biopharma Inc
  • Boston Pharmaceuticals Inc
  • Correvio Pharma Corp.
  • Daiichi Sankyo Co Ltd
  • Dong-A Socio Holdings Co Ltd
  • Edge Therapeutics Inc
  • Espero BioPharma Inc
  • G3 Pharmaceuticals Inc
  • Gilead Sciences Inc
  • HUYA Bioscience International
  • InCarda Therapeutics Inc
  • Merck & Co Inc
  • N-Gene Research Laboratories Inc
  • Nissan Chemical Industries Ltd
  • OMEICOS Therapeutics GmbH
  • The Geneva Biotech Center SA
  • Verseon Corp
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4745225
Adroll
adroll